PubMed
Gonadotropin-releasing hormone agonists and antagonists in assisted reproduction
Al-Inany et al., 2016
Hormonal & EndocrineFDA Approved / CompoundableS
Gonadorelin
GnRH / Factrel
Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a 10-amino acid hypothalamic peptide. FDA-approved for diagnosing hypogonadotropic hypogonadism and evaluating pituitary-gonadal function. Widely used in men on testosterone replacement therapy (TRT) to maintain testicular size, fertility, and endogenous testosterone production by preventing HPG axis suppression. Available through compounding pharmacies.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 2
- Research grade
- S
- Community score
- 140
- Trackers
- 3,216
Trend index
Overview
About Gonadorelin
Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a 10-amino acid hypothalamic peptide. FDA-approved for diagnosing hypogonadotropic hypogonadism and evaluating pituitary-gonadal function. Widely used in men on testosterone replacement therapy (TRT) to maintain testicular size, fertility, and endogenous testosterone production by preventing HPG axis suppression. Available through compounding pharmacies.
- Category
- Hormonal & Endocrine
- Regulatory status
- FDA Approved / Compoundable
- Also known as
- GnRH / Factrel
- Self-reports
- 25
Community
What 25 users report
25 community reports
Positive 97% · Neutral 3% · Negative 0%
Most reported benefits
Libido
181
Most reported side effects
Nausea
2
Injection site irritation
2
Headache
1
Dose distribution
Median: 100–200 mcg · Most common: 100–200 mcg
0–25
0
25–50
0
50–100
59
100–200
62
200–400
60
400–600
0
600–1000
0
1000–2000
0
2000+
0
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 235 days · Based on 23 repeat reporters
Research
Cited research (1)
Source
Help
Frequently asked
What do PeptIQ users report about Gonadorelin?
This page summarizes 25 anonymized self-reports from PeptIQ users who track Gonadorelin, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
What research is cited for Gonadorelin?
1 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Gonadorelin safe to use?
This wiki does not assess safety or recommend use. Gonadorelin is listed as FDA Approved / Compoundable. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Gonadorelin?
Research, primarily in animal models, suggests Gonadorelin may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Gonadorelin?
Gonadorelin is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Gonadorelin as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Gonadorelin?
The safety and effectiveness of Gonadorelin have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Gonadorelin?
While there are over 200 published studies on Gonadorelin, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source